Highlights in Multiple Myeloma from the Annual ASCO and EHA 2022 Meetings
Joshua Richter, MD
The Use of Biosimilars in Hematology/Oncology Practice
Dr. Charles Bennett, Dr. Marc Fishman, and Dr. Kevin Knopf
Are there any concerns or precautions clinicians should be aware of when switching a patient from IV daratumumab to subcutaneous?
Saad Z. Usmani, MD, FACP
What has been the overall impact of safety and efficacy in four-drug regimens compared to three-drug regimens?
Sagar Lonial, MD, FACP
FAQ
Developments in Newly Diagnosed Multiple Myeloma:
Considerations for Improved Patient Outcomes
Sagar Lonial, MD, FACP and Saad Z. Usmani, MD, FACP
What do you see for the future of myeloma treatment?
Joshua Richter, MD